The Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose Infusion.

Trial Profile

The Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose Infusion.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Dulaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 02 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Planned end date changed from Jul 2011 to Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top